4Bonadonna G, Brusamolion E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med, 1976, 294:405-410.
5Bonadonna G, Moliterni A, Zambetti M, et al. 30 years' follow up of randomized studies of adjuvant CMF in operable breast cancer: cohort study. BMJ, 2005, 330:217-220.
6Early Breast Cancer Trialist's Collaborative Group. Polychemotherapy for early breast cancer. An overview of the randomized trials.Lancet, 1998, 352(9132) :930-932.
7Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomided trials. Lancet, 1998,351 : 1451-1467.
8Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancers: updated finding from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst, 2001, 93:684-690.
9Ingle JN, Dowsett M, Cuzick J, et al. Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies. Cancer Res, 2009, 69 Suppl 2:66s.
10Pritchard KI, Shepherd LE, O'MaUey FP, et al. HER-2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med, 2006, 354:2103-2111.
2Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole- breast irradiation in stages Ⅰ and Ⅱ invasive breast cancer[ J]. Int J Radiat Oncol Biol Phys, 2014, 88:553-564.
